Ashland Inc. — Form 10-Q Summary
Business context and reporting period. Ashland is a global specialty ingredients and additives company, reporting for the three and six months ended March 31, 2023 (fiscal Q2 and first half of fiscal 2023). Its segments are Life Sciences, Personal Care, Specialty Additives and Intermediates. The prior-year comparison includes the Performance Adhesives business only as discontinued operations; Ashland sold it in February 2022.
Financial performance
- Quarter revenue and earnings: Sales were $603 million, essentially flat versus $604 million. Operating income fell to $83 million from $100 million. Continuing-operations income rose to $92 million from $38 million; diluted continuing-operations EPS was $1.68 versus $0.66. Net income was $91 million versus $786 million, with the prior-year amount including a $732 million after-tax gain on the Performance Adhesives sale.
- First-half results: Sales were $1.128 billion versus $1.115 billion; operating income was $120 million versus $142 million. Continuing-operations income was $134 million versus $70 million, and diluted continuing-operations EPS was $2.43 versus $1.20. Net income was $132 million versus $834 million, with the prior period likewise including the divestiture gain.
- Margins and adjusted performance: Gross profit was $197 million for the quarter, with gross margin of 32.7% versus 36.4%; first-half gross margin was 32.1% versus 34.1%. Adjusted EBITDA was $145 million for the quarter versus $163 million, and $254 million for the first half versus $269 million, according to the reconciliation. Management attributed the quarterly decline principally to higher plant manufacturing and energy costs, lower volumes and unfavorable foreign exchange, partly offset by pricing and mix.
- Segment trends, quarter versus prior year: Life Sciences sales rose to $240 million from $204 million and operating income rose to $58 million from $43 million. Personal Care sales declined to $167 million from $172 million and operating income to $14 million from $28 million. Specialty Additives sales declined to $161 million from $182 million and operating income to $15 million from $26 million. Intermediates sales declined to $51 million from $66 million and operating income to $17 million from $27 million.
- Cash flow and capital spending: First-half operating cash flow from continuing operations was $27 million versus $31 million. Capital expenditures were $58 million versus $37 million, resulting in free cash flow of negative $31 million versus negative $6 million. Cash and cash equivalents declined by $247 million to $399 million; the company cited dividends, share repurchases and capital spending among the main uses. Cash flow from discontinued operations was negative $47 million.
- Liquidity and debt: At March 31, cash was $399 million and reported debt was $1.328 billion, up from $1.270 billion at September 30, 2022. Available liquidity, including cash and unused revolving and foreign receivables-facility capacity, was $1.089 billion; restricted investments of $410 million are designated for asbestos and environmental obligations. The company reported compliance with debt covenants, a 1.6x net leverage ratio against a 4.0x maximum, and 10.6x interest coverage against a 3.0x minimum.
- Other financial items: The quarterly tax rate was a 1% benefit and the first-half rate was 5% expense, both significantly affected by favorable discrete tax items, including changes in uncertain tax positions. Restricted-investment gains also materially benefited net interest and other income: $20 million for the quarter and $41 million for the first half.
Changes, outlook and risks
- Quarter sales were affected by $74 million of favorable pricing, offset by $61 million of lower volume and $14 million of unfavorable foreign exchange. First-half pricing added $137 million, while lower volume and foreign exchange reduced sales by $87 million and $37 million, respectively. Higher operating costs pressured gross margin.
- Management lowered fiscal 2023 guidance, citing weaker global demand, continued customer destocking and external uncertainty. Sales are now expected at $2.3–$2.4 billion, versus prior guidance of $2.5–$2.7 billion; Adjusted EBITDA is expected at $580–$610 million, versus $600–$650 million. Inventory-control actions begun in April are expected to reduce second-half Adjusted EBITDA by approximately $20 million.
- Management noted demand weakness associated with China’s reopening in Personal Care and Specialty Additives, including extended unplanned shutdowns at the Nanjing facility, and a broader European slowdown affecting Specialty Additives. The quarter also included a $13 million impact from a U.S. winter storm on plant costs.
- Material uncertainties include economic and end-market conditions, customer destocking, inflation and raw-material costs, foreign exchange, supply-chain and plant disruptions, the Ukraine-Russia conflict and sanctions, and continuing uncertainty around COVID-19 effects. Sales to Ukraine, Russia and Belarus were less than 1% of consolidated sales.
- Asbestos reserves were $490 million in total for Ashland and Hercules, with estimated insurance receivables of $147 million. The filing describes reasonably possible future costs above current reserves under certain assumptions. Environmental remediation reserves were $193 million; the estimated upper end of reasonably possible future costs for identified sites was approximately $445 million. These estimates depend on significant assumptions and could change.
- Ashland completed a $100 million share-repurchase plan in April after quarter-end and amended its U.S. receivables sales program in April, extending its scheduled termination to April 2025 while reducing the buyer limit at certain times. The filing reports no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether weaker volumes, customer destocking and higher operating costs persist, and whether the reduced fiscal 2023 sales and Adjusted EBITDA outlook is achieved.
- The cash-flow impact of inventory levels, capital expenditures, dividends and share repurchases; the filing’s free-cash-flow discussion should be read alongside the $27 million of first-half operating cash flow and $58 million of capital spending.
- The assumptions, timing and insurance recoverability underlying asbestos and environmental reserves, including the disclosed potential cost ranges.
- The distinction between GAAP results and management’s non-GAAP Adjusted EBITDA and guidance; the filing does not reconcile forward-looking Adjusted EBITDA to GAAP net income because required information was not reasonably available.